Podcasts about promising

Hour 3 -- Another addition of Danny's Double Dips. The guys also dive into the top young stars in Bay Area Sports, and are later joined by Rich Aurilia to break down the Giants epic comeback capped off by a Bryce Eldridge Grand Slam. See omnystudio.com/listener for privacy information.

Hour 3 -- Another addition of Danny's Double Dips. The guys also dive into the top young stars in Bay Area Sports, and are later joined by Rich Aurilia to break down the Giants epic comeback capped off by a Bryce Eldridge Grand Slam. See omnystudio.com/listener for privacy information.

President Donald Trump has changed a lot about American foreign policy – and to many, America itself. But a lot of the issues facing this country were around long before he became president. Ben Rhodes' new book, All We Say: The Battle for American Identity: A History in 15 Speeches, tells the story of this country through speeches by figures like Ben Franklin, Martin Luther King, and yes, Donald Trump. We spoke with Ben about what those speeches reveal about being American, and what Trump's actions in Iran can tell us about his presidency and our country.And in headlines, President Trump continues to whiplash in Iran talks, we have a new pick for the Director of National Intelligence, and Kash Patel prepares the FBI for the World Cup.Show Notes: Check out Ben's book – https://tinyurl.com/pxpr6t8c Call Congress – 202-224-3121 Subscribe to the What A Day Newsletter – https://tinyurl.com/y4y2e9jy What A Day – YouTube – https://www.youtube.com/@whatadaypodcast Follow us on Instagram – https://www.instagram.com/crookedmedia/ For a transcript of this episode, please visit crooked.com/whataday

Funding novel therapeutics isn't just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and startup hurdles higher than most founders realize.Michael Rome, Managing Director at Foresite Capital, joined the Smart Biotech Scientist Podcast to dissect what's really driving funding decisions today, and what early-stage founders must do to stand out.Key topics discussed:The financial cycle of biotech investment before, during, and after the COVID-19 boom (02:47)Why investors are now focused on clear pathways to approved drugs and how founders should frame their proposals (06:10)The evolving importance of CMC expertise and manufacturing readiness for startups at different stages (07:44)Leadership traits and execution qualities investors appreciate in biotech founders and teams (09:18)Promising scientific and market areas including small molecule oncology, degraders, and heterobifunctional molecules (11:24)Practical advice for founders preparing for fundraising: focusing on unmet medical needs and market analysis (14:55)The impact of recent M&A activity and regulatory challenges at the FDA on the future of biotech investment (16:27)The importance of open communication and collaboration between scientists and investors (18:47)Smart insight: For those preparing their next fundraising push, Michael advised:Start with the end in mind: Outline the unmet need, the clinical and market pathway, and the product vision firstReverse engineer your innovation: Work backwards from market and regulatory needs to inform your technical approach, not the other way around.Frame your business case: Make it obvious to investors how your solution advances value in the ecosystemIf you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannConnect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.comNext: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

The Labour Party is promising cost-of-living relief for public transport users - pledging to cap their fares at no more than $20 a week if elected. National says it's just more irresponsible spending from Labour. Deputy political editor Craig McCulloch reports.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Doubling funding for the QEII National Trust would be the best bang for buck conservation investment the next Government could make, Federated Farmers says. The National Party recently announced it will double the trust's funding if it's part of the next Government. The Country's Jamie Mackay explained further. LISTEN ABOVESee omnystudio.com/listener for privacy information.

There's a sin you keep promising yourself you'll quit — and you're starting to wonder why you can't. This message walks through Revelation 8 and 9, the seven trumpets, and one uncomfortable truth most of us feel but rarely say out loud: sin doesn't stay a choice forever. At some point you stop choosing it, and it starts choosing you.We tend to read Revelation as a map of the end of the world. But the seventh seal doesn't open onto final destruction — it opens onto the Day of Atonement and a trumpet blast that, to the people who first heard it, meant one thing: a call to come home. The trumpets aren't only about the future. They're a warning about right now — about the thing quietly enslaving you, the way it dresses itself up as harmless, and the freedom that's actually possible when you finally name it. This isn't a timeline. It's an invitation.Support the show

Worship with us live online at ExploreGracePoint.com/church-onlineGracePoint Church2351 Rice Creek RdNew Brighton, MN 55112

We're learning from court transcripts that investigators tested a second male cruise passenger as a potential match to DNA recovered from Anna Kepner's rape kit. Pennsylvania volunteer firefighter confesses he's behind three weekend fires. Promising college football player shot day after his graduation ceremony. Sydney Silvagni reports. See omnystudio.com/listener for privacy information.

Pres. Trump is transforming politics and American values as an America First agenda takes hold. Or is it? Opposition remains entrenched, leftists are fighting harder to hold the levers of government, foreign policy, economic redistribution and racial inequities. Promising early GOP vote counts in California, or the snatching of victory in a fixed election system? Perspective and commentary on all of Thursday morning's biggest stories

A medical breakthrough in the fight against pancreatic cancer is showing promising results after decades of research. The experimental drug, taken once a day, extends patients' lives by slowing the progression of one of the deadliest cancers. Dr. Rachna Shroff, associate director of clinical investigations at the University of Arizona Comprehensive Cancer Center, joins Stephanie Sy for more. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Worship with us live online at ExploreGracePoint.com/church-onlineGracePoint Church2351 Rice Creek RdNew Brighton, MN 55112

AbstractThis article explores the often-overlooked tragedy of promising happiness through overcoming disability. It draws on qualitative interviews and focus groups with 36 adults with cerebral palsy to explore how medical discourse shapes the ways in which individuals are encouraged to pursue a good life, leading to unintended consequences. Sara Ahmed's theory of happiness is used to understand the dialectics of pursuing a good life through overcoming disability, revealing how medical interventions and discourse during childhood inadvertently contribute to feelings of inferiority and social alienation. The article highlights the need to reconsider how individuals with disabilities are encouraged to pursue a good life, emphasizing the paradox of disabling effects arising from attempts to minimize and overcome disability.https://www.sciencedirect.com/science/article/pii/S027795362500098X

Probiotics: A Promising Adjunct to Non-surgical Periodontal Therapy?By Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/probiotics-a-promising-adjunct-to-non-surgical-periodontal-therapy/Need CE? Start earning CE credits today at ⁠⁠⁠https://rdh.tv/ce⁠⁠⁠ Get daily dental hygiene articles at ⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠https://www.instagram.com/kara_rdh/⁠

In this segment, Mark is joined by Jacob Olidort, a Chief Research Officer and Director of American Security at the America First Policy Institute. They discuss the latest in what President Trump is calling "very promising talks" with Iran.

Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You

In this episode, ⁠Crawlspace Media⁠'s Tim Pilleri and Lance Reenstierna speak with survivor Jenaé Newell and director Ben Zand about their riveting new docuseries, The Cult of Natureboy. "The Cult of NatureBoy" is a new docuseries examining the dark reality behind online spiritual leader Eligio "NatureBoy" Bishop and his community, Carbon Nation. Promising a liberated "black utopia" through raw living, Bishop lured followers into a manipulative, abusive, and violent sex cult that ended with his life imprisonment. This episode was previously published on Missing on May 21st, 2026. Check out it: ⁠https://www.hulu.com/series/ce23eaed-d60d-472f-aa32-294619e7f438⁠. Follow Jenaé Newell: ⁠https://www.instagram.com/jenae.alexandrea⁠. Check out Jenaé Newell's book: ⁠https://www.amazon.com/Lesson-Learned-Wisdom-Granted-Divine/dp/B0CVF35Q12⁠. Zandland: ⁠https://www.zand.land/⁠. Check out Quince: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://quince.com/MISSING⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out Mint Mobile: ⁠⁠⁠⁠⁠⁠⁠⁠mintmobile.com/missing⁠⁠⁠⁠⁠⁠⁠⁠. Main podcast theme by Kevin Macleod. Check out his work at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://incompetech.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Additional music by David Williams. See his work at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://williamsflutes.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Missing: IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/MissingCSM/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. TT:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.tiktok.com/@missingcsm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. FB:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.facebook.com/MissingCSM⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. X:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/MissingCSM⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Spotify:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://open.spotify.com/show/0yRXkJrZC85otfT7oXMcri⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Youtube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/missingcsm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Apple:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://podcasts.apple.com/us/podcast/missing/id1006974447⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Crawlspace: IG:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/Crawlspacepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. TT:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.tiktok.com/@crawlspacepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. FB:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.facebook.com/Crawlspacepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. X:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/crawlspacepod.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Spotify:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://open.spotify.com/show/7iSnqnCf27NODdz0pJ1GvJ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Youtube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/crawlspace⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Apple:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://podcasts.apple.com/us/podcast/crawlspace-true-crime-mysteries/id1187326340⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out our entire network at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://crawlspace-media.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

When speaking about his departure, Jesus comforts his disciples by promising to send another Helper, the Holy Spirit.We'll see:- When the Spirit came.- How the Spirit teaches us all things.- How the Spirit brings us true peace.Time:MorningMinister:Rev. Joe PoppeTexts:John 14:25–27John 14Acts 2:1–4Series:John

In this new episode, Crawlspace Media's Tim Pilleri and Lance Reenstierna speak with survivor Jenaé Newell and director Ben Zand about their riveting new docuseries, The Cult of Natureboy. "The Cult of NatureBoy" is a new docuseries examining the dark reality behind online spiritual leader Eligio "NatureBoy" Bishop and his community, Carbon Nation. Promising a liberated "black utopia" through raw living, Bishop lured followers into a manipulative, abusive, and violent sex cult that ended with his life imprisonment. Check out it: https://www.hulu.com/series/ce23eaed-d60d-472f-aa32-294619e7f438. Follow Jenaé Newell: https://www.instagram.com/jenae.alexandrea. Check out Jenaé Newell's book: https://www.amazon.com/Lesson-Learned-Wisdom-Granted-Divine/dp/B0CVF35Q12. Zandland: https://www.zand.land/. Check out Quince: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://quince.com/MISSING⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out Mint Mobile: ⁠⁠⁠⁠⁠⁠⁠mintmobile.com/missing⁠⁠⁠⁠⁠⁠⁠. Main podcast theme by Kevin Macleod. Check out his work at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://incompetech.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Additional music by David Williams. See his work at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://williamsflutes.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Missing: IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/MissingCSM/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. TT:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.tiktok.com/@missingcsm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. FB:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.facebook.com/MissingCSM⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. X:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/MissingCSM⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Spotify:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://open.spotify.com/show/0yRXkJrZC85otfT7oXMcri⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Youtube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/missingcsm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Apple:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://podcasts.apple.com/us/podcast/missing/id1006974447⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Crawlspace: IG:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/Crawlspacepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. TT:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.tiktok.com/@crawlspacepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. FB:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.facebook.com/Crawlspacepodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. X:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/crawlspacepod.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Spotify:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://open.spotify.com/show/7iSnqnCf27NODdz0pJ1GvJ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Youtube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/crawlspace⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Apple:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://podcasts.apple.com/us/podcast/crawlspace-true-crime-mysteries/id1187326340⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out our entire network at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://crawlspace-media.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Britt Robson of MinnPost joins Korzo to talk about what Wolves fans can hope for this offseason before conversations about Harvard toughening up their grading policies, Pizza Hut locations going retro, and some sports topics during the Shot Clock!

A small 2026 randomized controlled trial found that adding low-dose dextromethorphan (DXM, 15 mg twice daily) to ongoing SSRI treatment significantly reduced Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores in adults with SSRI-resistant OCD, dropping from about 26.6 to 16.3 over 12 weeks versus little change on placebo. Strengths include its double-blind, placebo-controlled design, strong statistical effect size, excellent tolerability with no reported side effects, and alignment with the glutamatergic hypothesis of OCD. Limitations center on the tiny sample size (n=40), single-center location in Iran, lack of secondary outcomes or long-term follow-up, and potential pharmacokinetic variability from SSRI interactions; broader evidence from meta-analyses of other glutamatergic agents supports the approach but calls for larger confirmatory trials.

This interview is disseminated on behalf of Medicus Pharma Ltd.In this episode of Stocks to Watch, we are joined by Medicus Pharma (NASDAQ: MDCX) Executive Chairman and CEO Dr. Raza Bokhari to discuss the company's promising Phase 2 results for SkinJect, its innovative skin cancer treatment, and what lies ahead for the company across oncology, rare diseases, and prostate cancer.Learn more about Medicus Pharma: https://medicuspharma.com/Watch the full YouTube interview here: https://youtu.be/4GZIBnS2KZ0And follow us to stay updated: https://www.youtube.com/GlobalOneMedia 

One year on from when Pope Leo became head of the Catholic church and he remains a bit of an enigma. Is he a Conservative or Liberal? What did we learn from his clash with Donald Trump? Damian Thompson is joined by editor of The Pillar Ed Condon and two Spectator favourites – Freddy Gray and Mary Wakefield. Hosted on Acast. See acast.com/privacy for more information.

Dr. Brad Stanfield, a primary care physician from New Zealand and friend of this channel, did something heroic. He crowdfunded over $720,000 to put the “miracle drug” to the test. The results are finally in, and they aren't what anyone expected. I brought  @DrBradStanfield  onto the show to talk about what they mean. Get Early Access on Substackhttps://sgcarney.substack.com/Join this channel to get access to perks:https://www.youtube.com/channel/UC3PyxGKt94kLzVqkkjEgRFw/join

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleedingEditorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practiceHosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USAFeaturing: Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAJohn B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USAJoy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

In this episode of Making A Runner, Nic sits down with one of the most exciting emerging names in South African endurance running — George Kusche.From competing as an NCAA middle-distance athlete in the United States while studying actuarial science and statistics, to stepping away from running completely for a period of time, George's journey through the sport has been anything but conventional. But over the last few years, he has quietly rebuilt himself into an elite endurance athlete, running 2:13 for the marathon and an outstanding 5:41 debut at the Comrades Marathon.Together, Nic and George unpack:His transition from middle-distance track racing into marathon and ultra runningThe lessons he took from the NCAA system and his time in the USHis decision to self-coach and how he structures his trainingBuilding endurance without losing speedThe importance of long-term thinking and consistency in developmentBalancing elite-level training with work, life, and family commitmentsNutrition, race strategy, and lessons from his first Comrades MarathonMore than anything, this episode is a conversation about patience, progression, and trusting the process. George's story is a reminder that performance doesn't always follow a straight line — and that sometimes the best athletes are still quietly building towards their full potential.Whether you're training for your first marathon, chasing a Comrades goal, or simply trying to improve over the long term, this conversation is packed with practical insight and perspective from one of South Africa's rising endurance talents.We hope you enjoy the show, make sure to give the pod a follow and leave a review.

One year on from when Pope Leo became head of the Catholic church and he remains a bit of an enigma. Is he a Conservative or Liberal? What did we learn from his clash with Donald Trump? Damian Thompson is joined by editor of The Pillar Ed Condon and two Spectator favourites – Freddy Gray and Mary Wakefield. Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcasts. Contact us: podcast@spectator.co.uk Hosted on Acast. See acast.com/privacy for more information.

What if medicine could protect us against many respiratory viruses at once? In this episode of Ben Yeoh Chats, Ben speaks with Brian Wang, Programme Director at ARIA, the UK's Advanced Research and Invention Agency. Brian leads ARIA's Sustained Viral Resilience programme, which is exploring whether we can harness the innate immune system to create a new kind of preventive medicine.Brian explains why most people think about immunity through antibodies, vaccines and the adaptive immune system, while the innate immune system is broader, faster and potentially better suited to broad-spectrum protection. The challenge is that innate immunity has historically been harder to understand and harder to engineer safely.Ben and Brian discuss whether sustained innate immuno-prophylactics, or SIPs, could one day provide months of protection against flu, RSV, coronaviruses and future pandemic threats from a single dose. They also explore AI for biology, synthetic biology, pandemic preparedness after COVID, medical regulation, the UK science base, and ARIA's model for funding high-risk research.A conversation about innate immunity, preventive medicine, pandemic resilience, AI in biology, and how breakthroughs actually happen.Link to transcript: https://www.thendobetter.com/investing/2026/5/8/brian-wang-on-innate-immunity-aria-and-a-new-kind-of-preventive-medicineContents00:40 What we misunderstand about the immune system02:04 Could one medicine protect against many viruses?03:55 Innate versus adaptive immunity06:18 Why innate immunity was overlooked16:36 Breakthroughs in innate immunology21:09 Why start with respiratory viruses?25:47 How ARIA funds frontier science29:27 Promising approaches to SIPs34:13 AI for biology and its limits38:15 Brian's path to ARIA39:16 Pandemic preparedness after COVID44:03 Overrated / underrated47:27 The UK science ecosystem50:15 Medical regulation53:31 GLP-1s and wider biomedical discovery56:47 Upcoming ARIA calls01:02:10 Advice for scientists and builders

Nate says his date with Olivia felt almost too good to fail. They connected right away, skipped the awkward small talk, and even started talking about future plans before the night was over. But after what sounded like a promising first date in Palo Alto, Olivia suddenly vanished.See omnystudio.com/listener for privacy information.

Wednesday, May 6. The seven stories you need to know today.Read today's briefing.

Nick and Jonathan discuss how Aaron Rodgers could hurt the Steelers this offseason. Also, they talk about the first month of the Guardians season.

Join us at the Seven Figure Medicare Agent Summit: https://sevenfigure.com/summit/ In this episode of the Seven Figures or Bust Podcast, the hosts break down the biggest reasons why promising insurance agents fail and how to avoid those common pitfalls. They discuss critical factors like poor cash flow management, lack of focus, chasing too many opportunities at once, and relying on the wrong mindset—such as arrogance, laziness, or overthinking instead of taking action. The conversation also highlights the importance of tracking performance, staying disciplined, and developing real sales skills.Along the way, they mix in personal stories, industry insights, and practical advice to help agents build a sustainable and successful business. Overall, the episode is a candid and insightful look at what separates agents who thrive from those who burn out early in their careers.  

This podcast episode features a great in-depth discussion between Women in AAM Chairperson Marilyn Pearson and aviation journalist and pilot Elan Head on the evolving advanced air mobility and eVTOL industry. Elan emphasizes that while urban air taxis attract attention, the true excitement lies in the technological innovations—particularly in electric propulsion, autonomy, and flight controls—that could reshape aviation more broadly. They explore challenges in pilot training, noting that eVTOLs will still require significant skill and robust education despite early claims of simplicity. The conversation also addresses industry hype, delayed certification timelines, and resulting public skepticism, with Elan arguing that expectations were initially unrealistic. Promising early use cases such as tourism and short regional transport are highlighted as practical entry points. They also examine regulatory differences, global competition—especially from China—and the complexity of certification processes. Overall, the episode underscores both the transformative potential and the practical hurdles facing the AAM industry.

Rob, Jeremy, and Joe took some time from Thursday's BBMS to discuss yet another injury for the O's, this time to pitcher Trevor Rogers. Rogers landed on the 15-day IL with an illness, something that will keep him out until, at least, May 11th. Does it seem like injuries are ruining yet another promising O's season?

James Plowright of BuzzBeat joins the show again to discuss the Hornets' upcoming offseason. We touch on whether or not they should be aggressive this offseason and the types of targets we'd like to see them pursue.0:00 Intro and the Hornets early arrival6:32 Should they go all in now?15:08 Who is safe, who is expendable22:44 Physicality targetsYou can follow Yossi on:Twitter: https://twitter.com/YossiGozlanBlueSky: https://bsky.app/profile/yossigozlan.bsky.socialSalary cap sheets: www.capsheets.comThird Apron is available on all podcast providers. Please subscribe, rate, and share if you enjoyed this: https://linktr.ee/yossigozlanYou can also access Yossi's salary cap analysis on his Substack. Subscribe for $7 per month or $50 annually!: https://thirdapron.com

Read the full transcript here. How do we tell the difference between a theory that is incomplete and a theory that is simply wrong? What should count as success in fundamental physics when direct experiments are scarce? Can a theory be scientifically valuable long before it becomes directly testable? What does it mean for string theory to be both a candidate description of reality and a powerful mathematical toolkit? How often do people conflate the usefulness of a framework with proof that it describes the world? Can a theory be deeply generative even if it never becomes the final answer? What should we make of ideas that produce insights across mathematics, black holes, quantum fields, and condensed matter without yet pinning down our universe? Is there a meaningful difference between string theory as a family of possibilities and string theory as the true structure of nature? When a framework can describe many possible universes, is that a strength or a failure of specificity? Why has elegance been such a powerful guide in physics? When is beauty a fruitful heuristic, and when is it a dangerous seduction? Do humans mistake their own aesthetic preferences for clues about reality? Why have some of the strangest successful theories also turned out to be the most conceptually beautiful? How fair is the criticism that string theory was oversold? When promising frameworks fail to deliver quick experimental confirmation, how much hype should they be allowed to survive? Do fields become distorted when bold public narratives outrun what the evidence can support? How much do sociology, prestige, and intellectual fashion shape what physicists work on? Links: Christian's YouTube Channel Christian's work on ResearchGate and Google Scholar Christian Ferko studied math and physics at MIT before completing his PhD at the University of Chicago, focusing on string theory. He then performed postdoctoral research at the University of California, Davis, at the Center for Quantum Mathematics and Physics. Christian currently holds a joint appointment at Northeastern University and as a Junior Investigator at the Institute for Artificial Intelligence and Fundamental Interactions, a collaboration between MIT, Harvard, Northeastern, and Tufts. His research interests include string theory, quantum field theory, classical and quantum gravity, and the intersection between physics and AI. Staff Spencer Greenberg — Host + Director Ryan Kessler — Producer + Technical Lead WeAmplify — Transcriptionists Igor Scaldini — Marketing Consultant Music Broke for Free Josh Woodward Lee Rosevere Quiet Music for Tiny Robots wowamusic zapsplat.com Affiliates Clearer Thinking GuidedTrack Mind Ease Positly UpLift [Read more]

About this episode: Exacerbated by cuts to research funding and on-the-ground interventions, malaria remains one of the deadliest and most burdensome health crises across the globe. In this episode: Jane Carlton of the Johns Hopkins Malaria Research Institute details the state of the disease in 2026 and how tools like improved vaccines and genetically modified mosquitoes can bring us closer to elimination. Guest: Jane Carlton, PhD, is a Bloomberg distinguished professor and the director of the Johns Hopkins Malaria Research Institute. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: The Malaria Minute Podcast—The Johns Hopkins Malaria Research Institute World Malaria Day: Advocacy on Capitol Hill—Funding, Research, and Global Impact—Public Health On Call (April 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter. A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine). Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

See omnystudio.com/listener for privacy information.

Iran negotiations appear on the verge of collapse as the ceasefire deadline approaches, with U.S. officials preparing to travel for talks even as Iranian leadership signals it may not participate. Outrage is mounting after the IDF confirmed a soldier was responsible for smashing a statue of Jesus in southern Lebanon, prompting condemnation from Prime Minister Netanyahu and Christian leaders. FBI Director Kash Patel files a $250 million defamation lawsuit against The Atlantic, accusing the outlet of knowingly publishing false allegations about his conduct based on anonymous sources. A personalized mRNA vaccine for pancreatic cancer is showing early signs of promise in a small Phase 1 trial. California's governor's race is shifting following Eric Swalwell's exit amid scandal, with new polling showing former HHS Secretary Xavier Becerra gaining ground as a potential contender.   Birch Gold: Text MK to 989898 to join Birch Gold's Learn and Earn event by April 30!   Supersure Insurance: Simplify your business insurance and get a free coverage report at https://Supersure.com/Megyn Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week as usual, Blaine gives an overview of the podcast episode to begin (0:02).From there, he and Donovan begin the non-spoiler section with Adam's absence and where to see his band Sister Ray Davies on tour in the U.K. (0:50).After those notes, the hosts discuss what has. happened to 'Euphoria' as it gets off to a bad start (2:39). Then it's a brief conversation on why sites cover reality TV and what they think of it (9:37). Then it's a list of television shows this week and next week which all sound promising, some of which they'll cover (12:47).Continuing ideas and thoughts in non-spoilers, they discuss whether they'd recommend 'DTF St. Louis' from HBO (21:42) and general thoughts on 'Rooster' and its sixth episode (26:43).In spoilers, they break down why 'DTF St. Louis' worked or didn't (28:52) as well as what made 'Rooster' and its sixth episode a decent, but not great, one (48:41).For more, visit The Alabama Take. For the newsletter from the site, click this link to sign up.

HR1 - It's promising that Hawks found way to win game they should've lost In hour one Mike Johnson, Beau Morgan, and Ali Mac quickly touch on some of the biggest headlines around the local and national sports scene, recap and react to the Atlanta Hawks beating the New York Knicks in New York 107-106 last night in Game two of their first round playoff series with the Knicks, talk about how CJ McCollum carried the Hawks to victory last night, explain why they think the Hawks and CJ McCollum won Game two because they played great fourth quarter defense, let you hear Atlanta Falcons General Manager Ian Cunningham talk about if he's feeling any nerves about his first NFL Draft as an NFL GM, and if the goal of the draft for the team is the same as the team's goal was in free agency which was to raise the floor of the team. Mike, Ali, and Beau react to what Ian had to say, explain why they think the Falcons draft is all about continuing to raise the team's floor and create competition., recap and react to the Atlanta Braves winning their sixth game in a row after getting a 9-4 win over the Washington Nationals in D.C. last night in the first game of their four game series, talk about Bryce Elder having another quality start and bouncing back after a rough first inning, the Braves offense continuing to get timely hits, talk about Ronald Acuña Jr. getting a hit by a pitch twice in the game last night and having to exit the game early after getting hit the second time in the game, where he got hit in the hand, explain why they think Bryce Elder and the umpires last night handled Ronald Acuña Jr. getting hit twice perfectly, and then close out hour one by diving into the life of Ali Mac in Ali's Mac Drop!

The US military fires on and seizes an Iranian ship. Eight children were killed in the worst mass shooting in the country, since 2024.  President Trump announces an Oval Office Bible reading, amid a feud with the Pope. Promising new data from a pancreatic cancer vaccine trial. Plus, a hot air balloon makes an emergency landing in a backyard. Learn more about your ad choices. Visit podcastchoices.com/adchoices

A week after Hungarians booted out Viktor Orbán in favour of the pro-European Union Péter Magyar, Bulgarians headed to the polls considering the opposite: many are eager to elect the Russia-friendly Rumen Radev. Bruno Kaufmann joins us from Sofia. Plus, the latest on Iran, Israel and Lebanon.See omnystudio.com/listener for privacy information.

Send us Fan MailAfter the episode from 2 weeks ago where I covered Protein, creatine etc.  This week I'm tackling some of today's talked-about/hyped supplements and explain why it's crucial to approach them with a healthy dose of skepticism. Promising to clarify the role of trendy options like NAD, NAD+, and NMN, Can boosting naturally declining NAD levels truly reverse aging? And should you trust wellness gurus who pivot from publishing to selling supplements with scant evidence? With non-human studies forming the backbone of much of the current research, you'll hear why investing in healthy lifestyle habits like exercise and diet might be your best bet. I also call out the pattern of wellness figures capitalizing on fleeting trends, urging you to stay informed and cautious about what's genuinely effective for your health. Link to the study I mentionedAs always; HPNB still only has 5 billing cycles. So this means that you not only get 3 months FREE access, no obligation! BUT, if you decide you want to do the rest of the program, after only 5 months of paying $10/£8 a month you now get FREE LIFE TIME ACCESS! That's $50 max spend, in case you were wondering. Though I'm not terribly active on  Instagram and Facebook you can follow us there. I am however active on Threads so find me there! And, of course, you can always find us on our YouTube channel if you like your podcast in video form :) Visit healthypostnatalbody.com and get 3 months completely FREE access. No sales, no commitment, no BS. Email peter@healthypostnatalbody.com if you have any questions, comments or want to suggest a guest/topic      Playing us out; "I've got a whole lot of swing" by Thruline 

Today's guest would love to add more four and five-star picks to her reading list and she's curious about techniques that might help get her there. Kelly Krause is a first grade teacher who lives in Northwest Arkansas with her family. When Kelly discovers a winning author, it feels like a slam dunk to read the rest of their work. But when it comes to branching out in new directions, Kelly is not as confident. She's wondering whether devoting more time to reflecting on her reads by analyzing what's worked well or practicing the art of writing book reviews will help her pick more winning titles. Anne can't wait to explore this with Kelly today, along with sharing titles and authors Kelly may enjoy. Find the list of titles mentioned today on our show notes page at whatshouldireadnextpodcast.com/520. Our 15th Summer Reading Guide is coming your way next month! Creating this guide each year is truly a labor of love. Our Modern Mrs Darcy Book Club and What Should I Read Next? Patreon community members are automatically invited, and we'll also be offering our popular a la carte ticket. To make sure you get the 15th anniversary edition in your inbox and to find out how to join us for our live unboxing event, visit modernmrsdarcy.com/srg. Chapters 02:25 Meet Kelly 04:47 Kelly's reading dilemma 07:09 The Book of Hope: A Survival Guide for Trying Times by Jane Goodall and Douglas Abrams 08:44 The Kitchen Front by Jennifer Ryan 10:04 The Poet X by Elizabeth Acevedo 12:27 The Ministry of Time by Kaliane Bradley 28:06 The Lion Women of Tehran by Marjan Kamali 35:35 Kate & Frida by Kim Fay 38:58 Grief Cottage by Gail Godwin 50:29 What will Kelly read next? Learn more about your ad choices. Visit megaphone.fm/adchoices

Y'all may not realize it, but decisions made in Washington D.C. and state capitals shape your studio's operations, contracts and long-term viability—and typically feel out of your control.  Learn about the value of advocacy and how you have a stake (and more influence than you think) in Episode 723: Live from The HFA Show 2026: Lise Kuecker and Mike Goscinski, the Chief of Staff at the Health and Fitness Association.  Politics matter: legislation impacts your business whether you engage or not Shifting perceptions: gaining credibility and positioning as part of preventive healthcare Promising opportunities: GLP-1 research, Medicare fitness benefits and more Your voice counts: small businesses make policy real and tangible for lawmakers  Allies are everything: supporting HFA can unlock major wins for your business  Whether it's click-to-cancel, cold spa regulation or using HSA funds for fitness memberships, laws can make or break our industry. Uncover what you need to know in Episode 723.  The Health & Fitness Association is the only global trade association dedicated to protecting, promoting, and growing the health and fitness industry. We support active, healthy living by advocating for health and fitness businesses, delivering industry research and providing education that drives professional growth. Connect with HFA: YouTube  Instagram LinkedIn Health & Fitness Business magazine Catch you there, Lise   PS: Join 2,000+ studio owners who've decided to take control of their studio business and build their freedom empire. Subscribe HERE and join the party! www.studiogrow.co www.linkedin.com/company/studio-growco/

Tallstar's journey begins and ends.Resources:Mobilize.usStand With MinnesotaBook: Super Edition: Tallstar's Revenge Support us on Ko-fi! WCWITCast Ko-fiFollow us on BlueSky! WCWITCastFollow us on Instagram! WCWITCastCat Fact Sources:100 cats turned loose in an IKEA store to film commercial; 'making-of' spot becomes a Web hit - Los Angeles TimesIkea fills shop with cats for ad | Advertising | The GuardianYoutube - Behind the Scenes, Herding CatsVideo: 100 cats frolic at IKEA storeMusic:Happy Boy End Theme Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0https://creativecommons.org/licenses/by/4.0/This transformative podcast work constitutes a fair-use of any copyrighted material as provided for in section 107 of the US copyright law. Warrior Cats: What is That? is not endorsed or supported by Harper Collins and/or Working Partners. All views are our own.